Given that PAK4 overexpression promoted tamoxifen resistance, and that PAK4 displayed the only consistent correlation in both databases among group II PAKs to breast cancer patient outcome, and that depletion of PAK4 by siRNA gave very similar effects on ERα signaling as GNE-2861, this suggests that GNE-2861 may act to restore tamoxifen sensitivity by the inhibition of PAK4, although we cannot exclude possible effects onto other targets. Here, PAK4 is linked to breast carcinoma.